FTC opens investigation into Teva, escalating patent fight with pharma industry
Why has the FTC opened an investigation into Teva Pharmaceuticals?
The FTC has opened an investigation into Teva Pharmaceuticals due to the company's refusal to remove about two dozen patents for asthma and COPD inhalers from the FDA's Orange Book. The FTC argues that these patents are delaying generic competition and making it harder for lower-cost alternatives to enter the market6.
What actions have Congressional Democrats taken against Teva?
Congressional Democrats have pressured Teva Pharmaceuticals to voluntarily withdraw about two dozen patents for its asthma and COPD inhalers, accusing the company of making cosmetic changes to extend patent protections. The Federal Trade Commission has opened an investigation into Teva, escalating the months-long fight between Democrats and the pharmaceutical industry. Teva has until July 24 to cooperate with the FTC's demand.
How many companies did the FTC initially target for patent removal?
The FTC initially targeted 10 companies for patent removal, accusing them of improperly listing drug delivery device patents in the US Food and Drug Administration's Orange Book2.